GlassScriptPhysician profile
Gary Goldberg
NPI 1790764736
$14,867.74
in general payments reported to CMS, 2019-2025
59 companies · $4,635 in 2025
The $4,635 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $424 · 2021: $1,562 · 2022: $1,357 · 2023: $2,506 · 2024: $3,025 · 2025: $4,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,210 · Consulting Fee: $1,645 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,110 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,210.35 |
| Consulting Fee | $1,645.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,110.00 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,038.63 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Pfizer INC. | $1,524.66 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $1,046.71 | 2023-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $823.09 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $738.51 | 2021-2024 | Urolift |
| Dendreon Pharmaceuticals LLC | $588.81 | 2019-2025 | Provenge |
| Abbvie INC. | $578.82 | 2022-2025 | |
| Astellas Pharma US INC | $441.20 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $401.98 | 2019-2025 | Adstiladrin |
| Myovant Sciences INC. | $400.63 | 2021-2022 | |
| Antares Pharma, INC. | $387.99 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| 180 Medical, INC. | $354.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $316.73 | 2019-2025 | |
| Neotract INC. | $305.82 | 2019-2020 | |
| Urogen Pharma, INC. | $301.87 | 2023-2025 | Jelmyto |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.